Robbie Marcus
Stock Analyst at JP Morgan
(3.86)
# 640
Out of 5,147 analysts
180
Total ratings
55.08%
Success rate
8.22%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Overweight | $415 → $340 | $246.61 | +37.87% | 5 | Feb 19, 2026 | |
| MDT Medtronic | Maintains: Neutral | $105 → $100 | $97.66 | +2.40% | 13 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $135 → $100 | $76.85 | +30.12% | 14 | Feb 5, 2026 | |
| EW Edwards Lifesciences | Upgrades: Overweight | $90 → $100 | $86.47 | +15.65% | 7 | Dec 18, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $82 → $118 | $64.51 | +82.92% | 8 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $66 → $78 | $83.67 | -6.78% | 7 | Dec 5, 2025 | |
| HTFL HeartFlow | Maintains: Overweight | $36 → $40 | $23.16 | +72.71% | 2 | Nov 13, 2025 | |
| CNMD CONMED | Maintains: Neutral | $58 → $52 | $46.00 | +13.04% | 8 | Nov 6, 2025 | |
| RXST RxSight | Maintains: Underweight | $8 → $9 | $7.48 | +20.32% | 6 | Nov 6, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $115 → $100 | $98.44 | +1.58% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $17 | $18.67 | -8.94% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $73.43 | +2.14% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $12 → $13 | $11.38 | +14.24% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $16 | $18.30 | -12.57% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $16 | $14.58 | +9.74% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $15 → $7 | $8.16 | -14.22% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $77.18 | +55.48% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $20.37 | +76.73% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $387.46 | +14.85% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $503.51 | +34.06% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $8.78 | +48.06% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $31.26 | +27.96% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $84.27 | +6.80% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $25.47 | +96.31% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $1.86 | +330.11% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $344.39 | -27.41% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.10 | +14.75% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $116.35 | +1.42% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $133.75 | +16.64% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $120.40 | -66.78% | 2 | May 5, 2020 |
Insulet
Feb 19, 2026
Maintains: Overweight
Price Target: $415 → $340
Current: $246.61
Upside: +37.87%
Medtronic
Feb 18, 2026
Maintains: Neutral
Price Target: $105 → $100
Current: $97.66
Upside: +2.40%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $135 → $100
Current: $76.85
Upside: +30.12%
Edwards Lifesciences
Dec 18, 2025
Upgrades: Overweight
Price Target: $90 → $100
Current: $86.47
Upside: +15.65%
Inspire Medical Systems
Dec 16, 2025
Maintains: Neutral
Price Target: $82 → $118
Current: $64.51
Upside: +82.92%
The Cooper Companies
Dec 5, 2025
Maintains: Neutral
Price Target: $66 → $78
Current: $83.67
Upside: -6.78%
HeartFlow
Nov 13, 2025
Maintains: Overweight
Price Target: $36 → $40
Current: $23.16
Upside: +72.71%
CONMED
Nov 6, 2025
Maintains: Neutral
Price Target: $58 → $52
Current: $46.00
Upside: +13.04%
RxSight
Nov 6, 2025
Maintains: Underweight
Price Target: $8 → $9
Current: $7.48
Upside: +20.32%
Zimmer Biomet Holdings
Nov 6, 2025
Downgrades: Neutral
Price Target: $115 → $100
Current: $98.44
Upside: +1.58%
Nov 5, 2025
Maintains: Overweight
Price Target: $21 → $17
Current: $18.67
Upside: -8.94%
Oct 31, 2025
Maintains: Neutral
Price Target: $90 → $75
Current: $73.43
Upside: +2.14%
Oct 31, 2025
Maintains: Underweight
Price Target: $12 → $13
Current: $11.38
Upside: +14.24%
Oct 30, 2025
Maintains: Neutral
Price Target: $13 → $16
Current: $18.30
Upside: -12.57%
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $14.58
Upside: +9.74%
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $8.16
Upside: -14.22%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $77.18
Upside: +55.48%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $20.37
Upside: +76.73%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $387.46
Upside: +14.85%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $503.51
Upside: +34.06%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $8.78
Upside: +48.06%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $31.26
Upside: +27.96%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $84.27
Upside: +6.80%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $25.47
Upside: +96.31%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $1.86
Upside: +330.11%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $344.39
Upside: -27.41%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.10
Upside: +14.75%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $116.35
Upside: +1.42%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $133.75
Upside: +16.64%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $120.40
Upside: -66.78%